AbCellera Initiates Dosing Of Participants In A Phase 1 Clinical Trial Of ABCL635; Co. Initiated A Phase 1 Clinical Trial Of ABCL575, Which Is Being Developed For The Treatment Of Moderate-To-Severe Atopic Dermatitis
Author: Benzinga Newsdesk | August 07, 2025 04:11pm